K-ras codon 12 and 13 mutations are correlated with differential patterns of tumor cell dissemination in colorectal cancer patients

International Journal of Oncology

Volumn 24, Issue 6, 2004, Pages 1537-1544

  Conzelmann, Michael ^a   Linnemann, Ulrich ^b   Berger, Martin R ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Municipal Hospital Nürnberg Nord   (Germany)

Author keywords

Circulating epithelial cells; Cytokeratin 20; Disseminated tumor cells; Guanylylcyclase C; K ras

Indexed keywords

CYTOKERATIN 20; GUANYLATE CYCLASE; GUANYLATE CYCLASE C; MESSENGER RNA; UNCLASSIFIED DRUG; DNA; INTERMEDIATE FILAMENT PROTEIN; KRT20 PROTEIN, HUMAN; RNA;

ARTICLE; BONE MARROW; CANCER PATIENT; CODON; COLORECTAL CANCER; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER; LIVER BIOPSY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONCOGENE K RAS; PRIMARY TUMOR; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; AGED; COLORECTAL TUMOR; COMPARATIVE STUDY; GENETICS; INCIDENCE; LIVER TUMOR; LYMPH NODE METASTASIS; METABOLISM; MUTATION; ONCOGENE RAS; PATHOLOGY; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

AGED; BONE MARROW; CODON; COLORECTAL NEOPLASMS; DNA, NEOPLASM; FEMALE; GENES, RAS; GUANYLATE CYCLASE; HUMANS; INCIDENCE; INTERMEDIATE FILAMENT PROTEINS; KERATIN-20; LIVER; LIVER NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY;

EID: 16544367948     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Vogelstein B, Fearon E, Hamilton S, Kern S, Preisinger A, Leppert M, Nakamura Y, White R, Smits A and Bos J: Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532, 1988.
2. Jervoise H, Andreyev N, Norman A, Cunningham D, Oates J and Clarke P: Kirsten ras mutations in patients with colorectal cancer: the multicenter 'RASCAL' study. J Natl Cancer Inst 90: 675-684, 1998.
3. Brink M, De Goeij A, Weijenberg M, Roemen G, Lentjes M, Pachen M, Smits K, De Bruine A, Goldbohm R and van den Brandt P: K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 24: 703-710,2003.
4. Ward R, Todd A, Santiago F, O'Connor T and Hawkins N: Activation of the K-ras oncogene in colorectal neoplasms is associated with decreased apoptosis. Cancer 79: 1106-1113,1997.
5. Fan J and Bertino J: K-ras modulates the cell cycle via both positive and negative regulatory pathways. Oncogene 14: 2595-2607, 1997.
6. Cerrotini J, Caplin S, Saraga E, Givel J and Benhattar J: The type of K-ras mutation determines prognosis in colorectal cancer. Am J Surg 175: 198-202, 1998.
7. Span M, Moerkerk P, De Goeij A and Arends J: A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Int J Cancer 69: 241-245, 1996.
8. Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, Latteri M, La Farina M, Albanese I, Dardanoni G, Salerno S, Tomasino R, Labianca R, Gebbia N and Russo A: Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 13: 1438-1446, 2002.
9. Linnemann U, Schimanski C, Gebhardt C and Berger MR: Prognostic value of disseminated colorectal tumor cells in the liver: results of follow-up examinations. Int J Colorectal Dis, 2004 DOI 10.1007/S00384-003-0555-3.
10. Norheim Anderson S, Lovig T, Breivik J, Lund E, Gaudernack G, Meling G and Rognum T: K-ras mutations and prognosis in large-bowel carcinomas. Scand J Gastroenterol 32: 62-69, 1997.
11. Andreyev H, Tilsed J, Cunningham D, Sampson S, Norman A, Schneider H and Clarke P: K-ras mutations in patients with early colorectal cancers. Gut 41: 323-329, 1997.
12. Kressner U, Bjorheim J, Westring S, Wahlberg S, Pahlman L, Glimelius B, Lindmark G, Lindblom A and Borresen Dale A: Ki-ras mutations and prognosis in colorectal cancer. Eur J Cancer 34: 518-521, 1998.
13. Clarke G, Ryan E, Crowe J, O'Keane J and MacMathuna P: Tumor-derived mutated K-ras codon 12 expression in regional lymph nodes of stage II colorectal cancer patients is not associated with increased risk of cancer-related death. Int J Colorectal Dis 16:108-111,2001.
14. Goldberg R, Fleming T, Tangen C, Moertel C, MacDonald J, Haller D and Laurie J: Surgery for recurrent colon cancer: trategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med 129: 27-35, 1998.
15. Deans GT, Parks TG, Rowlands BJ and Spence RAJ: Prognostic factors in colorectal cancer. Br J Surg 79: 608-613, 1992.
16. Hayashi N, Ito I, Yanagisama A, Kato Y, Nakamori S, Imaoka S, Watanabe H, Ogawa M and Nakamura Y: Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet 345: 1257-1259, 1995.
17. Dieterle C, Conzelmann M, Linnemann U and Berger MR: Investigation of isolated tumor cells by PCR-RFLP detection of K-ras mutations in tumor, mucosa, liver, lymph node and bone marrow samples of 199 colorectal cancer patients. Clin Cancer Res 10: 641-650, 2004.
18. Thebo J, Senagore A, Reinhold D and Stapleton S: Molecular staging of colorectal cancer. Dis Colon Rectum 43: 155-162, 2000.
19. Yun K, Merrie A, Gunn J, Phillips L and McCall J: Keratin 20 is a specific marker of submicroscopic lymph node metastases in colorectal cancer: validitation by K-ras mutations. J Pathol 191: 21-26, 2000.
20. Nakamori S, Kameyama M, Furukawa H, Takeda O, Sugai S, Imaoka S and Nakamura Y: Genetic detection of colorectal cancer cells in circulation and lymph nodes. Dis Colon Rectum 40 (Suppl): 29-36, 1997.
21. Schimanski CC, Linnemann U and Berger MR: Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver. Cancer Res 59: 5169-5175, 1999.
22. Etoh T, Hiroka U, Hiroshi I, Sato K, Utsunomiya T, Barnard G, Kitano S and Mori M: Clinical significance of K-ras mutations in intraoperative tumor drainage blood from patients with colorectal carcinoma. Ann Surg Oncol 8: 407-412, 2001.
23. Tortola S, Steinert R, Hantschick M, Peinado M, Gastinger I, Stosiek P, Lippert H, Schlegel W and Reymond M: Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer. J Clin Oncol 19: 2837-2843,2001
24. Samowitz W, Curtin K, Schaffer D, Robertson M, Leppert M and Slattery M: Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a pupolation based study. Cancer Epidemiol Biomarkers Prev 9: 1193-1197, 2000.
25. Leinung S, Wuerl P, Weiss C, Roeder I and Schoenfelder M: Cytokeratin-positive cells in bone marrow in comparison with other prognostic factors in colon carcinoma. Langenbecks Arch Chir 385: 337-343, 2000.
26. Rosenberg R, Hoos A, Mueller J, Baier P, Strieker D, Werner M, Nekarda H and Siewert J: Prognostic significance of cytokeratin 20 reverse transcriptase polymerase chain reaction in lymph nodes of node-negative colorectal cancer patients. J Clin Oncol 204: 1049-1055,2002.
27. Yokoyama N, Shirai Y, Ajioka Y, Nagakura S, Suda T and Hatakeyama K: Immunohistochemically detected hepatic micrometastases predict a high risk of intrahepatic recurrence after resection of colorectal carcinoma liver metastases. Cancer 94: 1642-1647,2002.
28. Conzelmann M, Dieterle C, Linnemann U and Berger MR: Cytokeratin 20 and guanylylcyclase C mRNA is largely present in lymph node and liver specimens of colorectal cancer patients. Int J Cancer 107: 617-628, 2003.
29. Weitz J, Kienle P, Magener A, Koch M, Schroedel A, Willeke F, Autschbach F, Lacroix J, Lehnert T, Herfarth C and von Knebel Doeberitz M: Detection of disseminated tumor cells in lymph nodes, blood and bone marrow. Clin Cancer Res 5: 1830-1836,1999.
30. Liefers GJ, Cleton-Jansen AM, van de Velde CJH, Hermans J, van Krieken HJM, Cornelisse CJ and Tollenaar RAEM: Micrometastases and survival in stage II colorectal cancer. N Engl J Med 339: 223-228, 1998.
31. Cagir B, Gelmann A, Park J, Fava T, Tenkelevitch A, Bittner EW, Weaver EJ, Palazzo JP, Weinberg D, Fry RD and Waldmann SA: Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer. Ann Intern Med 131: 805-812,1999
32. Merrie A, van Rij A, Dennett E, Phillips L, Yun K and McCall Y: Prognostic significance of occult metastases in colon cancer. Dis Colon Rectum 46: 221-231, 2003.
33. Noura S, Yamamoto H, Ohnishi T, Masuda N, Matsumoto T, Takayama O, Fujunaga H, Miyake Y, Ikenaga M, Ikeda M, Sekimoto M, Mtsuura M and Monden M: Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry. J Clin Oncol 20: 4232-4241, 2002.
34. Yamaguchi K, Takagi Y, Aoki S, Futamura M and Saji S: Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann Surg 232: 58-65, 2000.
35. Bessa X, Elizalde J, Boix L, Pinol V, Lacy A, Salo J, Pique J and Castells A: Lack of prognostic influence of circulating tumor cells in peripheral blood of patients with colorectal cancer. Gastroenterology 120: 1084-1092,2001.
36. Wyld D, Selby P, Perren T, Jonas S, Allen-Mersh T, Wheeldon J and Burchili S: Detection of colorectal cancer cells in peripheral blood by reverse-transcriptase polymerase chain reaction for cytokeratin 20. Int J Cancer 79: 288-293, 1998.
37. Soeth E, Roeder C, Juhl H, Krueger U, Kremer B and Kalthoff H: The detection of disseminated tumor cells in bone marrow from colorectal cancer patients by a cytokeratin-20-specific nested reverse-transcriptase-polymerase-chain reaction is related to the stage of the disease. Int J Cancer 69: 278-282, 1996.
38. Vlems F, Diepstra J, Punt C, Ligtenberg M, Cornelissen I, van Krieken J, Wobbes T, van Muijen G and Ruers T: Detection of disseminated tumor cells in blood and bone marrow samples of patients undergoing hepatic resection for metastasis of colorectal cancer. Br J Surg 90: 989-995, 2003.
39. Bessa X, Pinol V, Castellvi Bel S, Piazuelo E, Lacy A, Elizalde J, Pique J and Castells A: Prognostic value of postoperative detection of blood circulating tumor cells in patients with colorectal cancer operated on for cure. Ann Surg 237: 368-375, 2003.
40. Waldmann S, Cagir B, Rakinic J, Fry R, Goldstein S, Isenberg G, Barber M, Biswas S, Minimo C, Palazzo J, Park P and Weinberg D: Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer. Br J ancer 41: 310-315, 1998.
41. Nordgard O, Aloysius T, Todnem K, Heikkila R and Ogreid D: Detection of lymph node micrometastases in colorectal cancer.Scand J Gastroenterol 2: 125-132, 2003.
42. Vlems F, Ruers T, Punt C, Wobbes T and van Muijen G: Relevance of disseminated tumor cells in blood and bone marrow of patients with solid epithelial tumors in perspective. Eur J Surg Oncol 29: 289-302, 2003.
43. Hardingham JE, Hewett PJ, Sage RE, Finch JL, Nutall JD, Kotasek D and Dobrovic A: Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease. Int J Cancer 89: 8-13, 2000.
44. Soeth E, Vogel I, Roder C, Juhl C, Marxsen J, Kriiger U, Henne Bruns D, Kremer B and Kalthoff H: Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. Cancer Res 57: 3106-3110 1997.